Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 92, Issue 1, 2004, Pages 93-100

  Look, Katherine Y ^a   Bookman, Michael A ^b   Schol, Jessie ^b   Herzog, Thomas J ^c   Rocereto, Thomas ^d   Vinters, Jennifer ^e  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^e INDIANA UNIVERSITY   (United States)

Author keywords

CPG; Feasibility trial; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; PACLITAXEL;

ABSCESS; ADULT; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ADMINISTRATION; EPITHELIUM CELL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEMATOLOGIC DISEASE; HUMAN; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; OVARY TUMOR; PATHOLOGY; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PERITONEUM TUMOR; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0742324884     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.09.019     Document Type: Article

References (27)

1. McGuire W.P., Hoskins W.J., Brady M.F.et al. Cyclophosphamide and cisplatin with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334:2000;1-6.
2. Piccart M.J., Bertelsen K., James K.et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl. Cancer Inst. 92:2000;699-708.
3. Armstrong D.K., O'Reilly S., Bookman M.et al. A phase I study of Topotecan (T), Cisplatin (C) and Paclitaxel (P) in newly diagnosed epithelial ovarian cancer: a Gynecologic Oncology Group (GOG 9602) study. Proc. Am. Soc. Clin. Oncol. 17:1998;350. [Abstr# 1351].
4. Rose P.G., Rodriguez M., Waggoner S.et al. Phase I study of paclitaxel, carboplatin and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 18(16):2000;2957-2962.
5. Huang C., Chubb S., Hertel L.W., Grindey G.B., Plunkett W. Action of 2′2′ difluorodeoxycytidine on DNA synthesis. Cancer Res. 51(22):1991;6110-6117.
6. Cartee L., Kucera G.L. Gemcitabine induced programmed cell death and activates protein kinase C in BG-1 human ovarian cancer cells. Cancer Chemother. Pharmacol. 41:1998;403-412.
7. Lund B., Hansen O.P., Theilade K., Hansen M., Neijt J.P. Phase II study of gemcitabine (2′2′difluorodeoxycytidine) in previously treated ovarian cancer patients. J. Natl. Cancer Inst. 86:1994;1530-1533.
8. Shapiro J.D., Millward M.J., Rischin D.et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol. Oncol. 63:1996;89-93.
9. van Moorsel C.J., Pinedo H.M., Veerman G.et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small cell lung cancer cell lines. Br. J. Cancer. 80(7):1999;981-990.
10. Ricci S., Antonuzzo A., Galli L.et al. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced non-small cell lung cancer. Cancer. 89(8):2000;1714- 1719.
11. Ozols R.F., Bundy B.N., Greer B.E.et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin Oncol. 21(17):2003;3194-3200.
12. DuBois A., Lueck H.J., Meier W.et al. Cisplatin/paclitaxel vs. carboplatin/paclitaxel in ovarian cancer: update of an Arbeitgemeinschaft Gynaekologische Onkologie (AGO) study group trial. Proc. Am. Soc. Clin. Oncol. 18:1999;356. [Abst# 1374].
13. Hansen S.W., Anderson H., Boman K.et al. Gemcitabine, Carboplatin, Paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB-IV. Proc. Am. Soc. Clin. Oncol. 18:1999;357. [Abst# 1379].
14. Geertsen P., Hansen M., Stroyer I., Hansen S.W. Combination chemotherapy with platinum, paclitaxel and gemcitabine in patients with relapsed ovarian carcinoma. Proc. Am. Soc. Clin. Oncol. 18:1999;361. [Abst# 1395].
15. Jelliffe R.W. Creatinine clearance: bedside estimate. Ann. Intern. Med. 79:1973;604-605.
16. Kelly K., Mikhaeel-Kamel N., Pan Z., Murphy J., Prindiville S., Bunn P.A. Jr. A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer. A University of Colorado Cancer Center study. Clin. Cancer Res. 6(9):2000;3474-3479.
17. Creemers G.J., Bolis G., Gore M.et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J. Clin. Oncol. 14(12):1996;3056-3061.
18. Muggia F.M., Hainsworth J.D., Jeffers S.et al. Phase II study of liposomal doxorubicin in refractory ovary cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. 15(3):1997;987-993.
19. Rose P.G., Blessing J.A., Mayer A.R., Homesley H.D. Prolonged oral etoposide as second line therapy for platinum resistant and platinum sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 16(2):1998;405-410.
20. Eisenhauer E.A., ten Bokkel Huinink W.W., Swenerton K.D.et al. European-Canadian randomized trial of paclitaxel in replapsed ovarian cancer: high-dose versus low dose and long versus short duration. J. Clin. Oncol. 12(12):1994;2654-2666.
21. Bookman M.A., McGuire W.P. III, Kilpatrick D.et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J. Clin. Oncol. 14(6):1996;1895-1902.
22. Rowinsky E.K., Gilbert M., McGuire W.P.et al. Sequences of taxol and cisplatin: a phase I pharmacologic study. J. Clin. Oncol. 9(9):1991;1692-1703.
23. Jodrell D.I., Egorin M.J., Cannetta R.M.et al. Relationships between carboplatin exposure and tumor response toxicity in patients with ovarian cancer. J. Clin. Oncol. 10(4):1992;520-528.
24. Fleming G.F., Fowler J.M., Waggoner S.E.et al. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study. J. Clin. Oncol. 19(4):2001;1021-1029.
25. Hussein A., Birch R., Waller J.et al. Preliminary results of a randomized study comparing paclitaxel and carboplatin (PC) with or without gemcitabine (G) in newly diagnosed non small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 19:2000;504 A. [#1973].
26. Greco F.A., Burris H.A. III, Hainsworth J.D. Gemcitabine, paclitaxel and carboplatin for advanced non-small cell lung cancer. Oncology. 14(7):2000;31-34.
27. Hansen S.W. Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma. Semin. Oncol. 29:2002;17-19.